Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

44.85
-1.3100-2.84%
Post-market: 44.80-0.0500-0.11%19:54 EDT
Volume:859.92K
Turnover:38.70M
Market Cap:2.75B
PE:10.60
High:46.06
Open:45.96
Low:44.27
Close:46.16
Loading ...

Protagonist Therapeutics Reports Granting of Inducement Award

ACCESS Newswire
·
17 Apr

Protagonist Therapeutics’ Icotrokinra: A Promising Buy Rating Backed by Strong Efficacy, Safety, and Financial Prospects

TIPRANKS
·
11 Apr

Protagonist Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Apr

Protagonist Therapeutics: Promising Clinical Data and Strategic Expansion Drive Buy Rating

TIPRANKS
·
11 Apr

Promising Potential of Protagonist Therapeutics’ Icotrokinra in Psoriasis Treatment: A Buy Recommendation by Roger Song

TIPRANKS
·
10 Apr

Protagonist Therapeutics on Pace for Record Losing Streak -- Data Talk

Dow Jones
·
02 Apr

Protagonist Therapeutics Price Target Maintained With a $70.00/Share by Wedbush

Dow Jones
·
28 Mar

BRIEF-Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA

Reuters
·
21 Mar

Protagonist Therapeutics Inc - Transition to Takeda of Leadership for Nda Preparation Underway

THOMSON REUTERS
·
21 Mar

Protagonist Therapeutics- Takeda to Lead Regulatory Strategy for Rusfertide in Polycythemia Vera Nda

THOMSON REUTERS
·
21 Mar

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?

Insider Monkey
·
19 Mar

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

ACCESS Newswire
·
18 Mar

Protagonist Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
12 Mar

PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study

Zacks
·
12 Mar

Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating

MT Newswires Live
·
11 Mar

Protagonist Therapeutics Inc : Wedbush Raises Target Price to $70 From $58

THOMSON REUTERS
·
11 Mar

Protagonist Therapeutics Soars as Icotrokinra Drives Breakthrough Success

GuruFocus.com
·
11 Mar

Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday

Insider Monkey
·
11 Mar

Protagonist Therapeutics price target raised to $80 from $54 at H.C. Wainwright

TIPRANKS
·
11 Mar

Top Midday Gainers

MT Newswires Live
·
11 Mar